About one in three people with major depressive disorder do not respond adequately to two or more antidepressant medications, a pattern clinicians call treatment-resistant depression (Mayo Clinic). That number represents millions of people who followed the standard path, tried the medications, waited the recommended weeks, and still felt the full weight of depression. If that is your experience, you are not at the end of your options.
What “Treatment-Resistant” Actually Means
The term sounds final. It is not. Treatment-resistant depression (TRD) is a clinical designation, not a verdict. Most clinicians apply it when a patient has not responded adequately to at least two antidepressant medications taken at therapeutic doses for a sufficient duration, typically six to eight weeks each. The label exists to signal that something different is needed, not that recovery is out of reach.
Depression itself is one of the most common mental health conditions in the world. Symptoms can include persistent sadness, loss of interest in activities that once brought pleasure, changes in sleep and appetite, difficulty concentrating, fatigue, and in some cases thoughts of death or suicide (Mayo Clinic). When those symptoms persist despite multiple treatment attempts, the diagnosis shifts, and so should the approach.
At Psychotherapy Care Center, we see patients at exactly this stage. People who have spent months or years trying medications that worked for someone else, following the advice of providers who were doing their best with first-line options. TRD is not a personal failure or a sign that something is fundamentally broken. It is clinical information that points toward a different kind of care.
Why Standard Antidepressants Do Not Work for Everyone
Most first-line antidepressants belong to two classes: selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). These medications work by increasing the availability of specific neurotransmitters in the brain. For many people, they are effective. For others, they are not, and the reasons vary considerably from person to person.
Genetic differences in how individuals metabolize medications can mean that a standard dose is either insufficient or poorly tolerated before it has had a chance to work. Underlying conditions including thyroid dysfunction, chronic inflammation, or sleep disorders can sustain depressive symptoms independently of the neurotransmitter systems these medications target. And for some patients, the biology of their depression involves pathways that SSRIs and SNRIs simply do not reach directly.
None of these factors are visible from the outside. They require careful evaluation of your full treatment history, not just a list of what you have tried. That evaluation is where we start with every patient who comes to us after an extended course of unsuccessful treatment.
SPRAVATO® and What Makes It Different
In 2019, the U.S. Food and Drug Administration approved SPRAVATO® (esketamine) nasal spray as the first medication of its kind specifically indicated for treatment-resistant depression, available only through certified healthcare settings (Janssen Pharmaceuticals, 2019). In 2024, it received an additional approval as the first and only monotherapy for adults with TRD, meaning it can be prescribed as a standalone treatment rather than only alongside an oral antidepressant (Johnson and Johnson, 2025).
SPRAVATO® works through a different mechanism than standard antidepressants, acting on the glutamate system rather than the serotonin or norepinephrine pathways. This distinction matters for patients whose depression has not responded to medications that work on those monoamine pathways. Clinical evidence supporting its approval showed meaningful symptom reduction in patients who had failed multiple prior treatments, with some patients experiencing relief within 24 hours to a few days.
Psychotherapy Care Center is a certified SPRAVATO® REMS treatment center. That certification means our clinical staff are trained in the specific protocols required for safe administration, and that every session takes place under qualified healthcare supervision. SPRAVATO® is not a medication patients take at home. It is administered in our clinic, and patients are monitored on-site for a minimum of two hours following each session. Because of this, patients need a designated driver for every appointment. Results vary by individual, and not every patient with TRD is a candidate for SPRAVATO®. An evaluation is required to determine whether this treatment is appropriate for your history and current health status.
What Evaluation and Treatment Look Like at Our Clinics
Before we recommend any course of treatment, we conduct a thorough assessment of your full psychiatric and medication history. That includes reviewing prior medication trials for dose and duration, screening for medical or physiological factors that may be sustaining depressive symptoms, and exploring what has and has not been tried. We do not start with a recommendation. We start with a clear picture of where you are.
For patients who are appropriate candidates, SPRAVATO® sessions at Psychotherapy Care Center follow a consistent structure. You arrive and settle into a comfortable, quiet space. You self-administer the nasal spray under the guidance of our staff. We monitor your blood pressure and overall status for a minimum of two hours before you are cleared to leave with your driver. Most patients feel back to their normal baseline after a full night of sleep. Maintenance sessions continue on a schedule determined by your clinical team, with the goal of reducing relapse risk over time.
For patients who are not SPRAVATO® candidates or who want to explore other options alongside it, we also provide traditional psychotherapy, comprehensive medication management led by our team of board-certified Advanced Practice Nurses, and non-traditional approaches including nutritional therapy, breath therapy, and guided imagery. We discuss all relevant options with every patient. The decision about how to move forward is always made collaboratively, with your history, preferences, and goals informing the plan. We encourage you to discuss your full range of options with your provider before committing to any single path.
A Direct Word on Cost and Insurance
Advanced treatment raises real cost questions, and we would rather address them plainly than leave you to guess.
SPRAVATO® has broader insurance coverage than many patients expect. Because it is FDA-approved and carries formal clinical evidence, it is covered by a significant number of major insurers. Psychotherapy Care Center accepts Aetna, AmeriHealth, Anthem, BlueCross BlueShield, Cigna/Evernorth, Magnacare, Medicare, Medicaid, Optum, Oxford Health Plans, UMR, and United Healthcare, among others. Coverage for SPRAVATO® specifically depends on your plan and whether specific criteria are met, and we verify insurance before your first treatment session so you are not surprised after the fact.
For patients with questions about coverage or out-of-pocket costs, our team will walk through the financial details before you commit to anything. Cost is a real factor in whether people can access care, and we take that seriously. You can learn more about our services at our Jersey City and Union City locations, or contact us directly with any questions about your specific coverage.
Frequently Asked Questions
How do I know if I qualify as treatment-resistant? The standard clinical threshold is two or more antidepressant medications tried at adequate doses for adequate duration without sufficient response. If you are not sure whether your prior trials meet that standard, the evaluation process will clarify it. Some patients who believe they are treatment-resistant have not yet completed a full therapeutic trial. For others, the history is clear from the first conversation.
Is SPRAVATO® the same as ketamine? SPRAVATO® (esketamine) is a derivative of ketamine and works through a related mechanism, but it is a distinct, FDA-approved medication formulated specifically for depression. It is administered as a nasal spray in a certified clinical setting under healthcare supervision, which is a meaningfully different context from other forms of ketamine use. Every SPRAVATO® patient at Psychotherapy Care Center is screened for appropriateness before treatment begins.
Does insurance cover SPRAVATO® treatment? Coverage varies by plan, but SPRAVATO® has significantly broader insurance support than many patients assume, partly because of its FDA approval status and clinical evidence base. We accept most major insurance plans and handle coverage verification before your first session. If you are unsure about your plan, our team can help you check before your appointment.
Do I need a referral to be evaluated? No referral is required to contact Psychotherapy Care Center and request an evaluation. You can reach us by phone or through our online appointment request form. We respond within 24 hours.
What if SPRAVATO® is not right for me? Not every patient with TRD is a candidate for SPRAVATO®, and that determination is made through evaluation, not assumption. If SPRAVATO® is not the right fit for your history or health status, we will discuss what other options may be appropriate, including comprehensive medication management, psychotherapy, and integrative approaches. We do not default to a single protocol for every patient.
Key Takeaways
- Treatment-resistant depression is a clinical designation applied when two or more antidepressants at adequate doses and duration have not produced sufficient relief. It is not a life sentence.
- Standard antidepressants target serotonin and norepinephrine pathways. For some patients, the biology of their depression involves other systems those medications do not directly reach.
- SPRAVATO® (esketamine) is the first FDA-approved nasal spray medication for TRD, available only through certified clinical settings like Psychotherapy Care Center.
- Every SPRAVATO® session is conducted in our clinic with a minimum two-hour observation period. Patients need a driver home following each session.
- Psychotherapy Care Center accepts most major insurance plans, and our team verifies SPRAVATO® coverage before treatment begins.
Conclusion
If you have been through multiple antidepressants without finding relief, that history is information, and it deserves a clinical response that matches what it actually tells us. At Psychotherapy Care Center, we start every TRD evaluation by taking that history seriously and asking what it points to. We serve patients across Jersey City, Union City, and throughout New Jersey, with telehealth options available for those who cannot come in person. Call us at (201) 604-0377 or submit an appointment request through our website, and we will contact you within 24 hours to discuss what evaluation looks like for your specific situation.
References
Mayo Clinic. (n.d.). Depression (major depressive disorder) — Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
Janssen Pharmaceuticals. (2019). Janssen announces U.S. FDA approval of SPRAVATO™ (esketamine) CIII nasal spray for adults with treatment-resistant depression. https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief
Johnson and Johnson. (2025). SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression, including SPRAVATO® (esketamine), should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Results vary by individual, and not every treatment described is appropriate for every patient. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.
